CORE
LIVE

Serial Number

79358656

Owner

Core Biogenesis

Filing Date

Oct 10, 2022

Add to watchlist:

No watchlists yet
View on USPTO

CORE Trademark

Serial Number: 79358656 • Registration: 7942982

CORE is a trademark filed by Core Biogenesis on October 10, 2022. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific). The application is currently registered and active.

Owner Contact Info

Core Biogenesis (3 trademarks)

850 boulevard Sébastien Brant

Entity Type: 35

Trademark Details

Filing Date

October 10, 2022

Registration Date

September 16, 2025

Published for Opposition

January 14, 2025

Goods & Services

Apparatus for the regeneration of stem cells for medical use

Chemical research; scientific research; biological research; chemical analysis; molecular research; genetic research; cell research

Chemicals, namely, for use in industry and science; proteins and other molecules for use in medical research; proteins as industrial chemicals for manufacturing or as ingredients in cell culture media and diagnostic preparations; proteins and other biomolecules of pharmaceuticals (biopharmaceuticals); enzymes and other molecules for industrial and scientific use; biological preparations for use in industry and science; cell growth media for growing cells and for use in scientific, biological and biotechnological research; biological preparations, namely, fats and lipids, proteins, peptides, living cells, living tissue, laboratory-grown living cells, laboratory-grown living tissue for use in industry and science

Pharmaceutical; stem cells for medical, clinical, pharmaceutical and veterinary use; cell growth media for growing cells for medical, clinical, pharmaceutical and veterinary use; chemical preparations for medical, clinical, pharmaceutical and veterinary use; biological preparations for medical, clinical, pharmaceutical and veterinary use; bacterial preparations for medical, clinical, pharmaceutical and veterinary use; microbiological culture media for medical, clinical, pharmaceutical and veterinary use; enzyme preparations for medical, clinical, pharmaceutical and veterinary use; diagnostic preparations for medical, clinical, pharmaceutical and veterinary use; biological products in the nature of cell preparations for medical, clinical, pharmaceutical and veterinary use

Filing History

FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Dec 16, 2025 FICR
REGISTERED-PRINCIPAL REGISTER
Sep 16, 2025 R.PR
TTAB RELEASE CASE TO TRADEMARKS
Aug 23, 2025 TMBN
OPPOSITION TERMINATED NO. 999999
Aug 23, 2025 OP.T
OPPOSITION SUSTAINED NO. 999999
Aug 23, 2025 OP.S
REFUSAL PROCESSED BY IB
May 31, 2025 RFNP
EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED
May 15, 2025 ETOP
OPPOSITION INSTITUTED NO. 999999
May 15, 2025 OP.I
OPPOSITION NOTICE (IB REFUSAL) SENT TO IB
May 13, 2025 OPNS
OPPOSITION NOTICE (IB REFUSAL) CREATED
May 13, 2025 OPNC
EXTENSION OF TIME TO OPPOSE RECEIVED
Jan 22, 2025 ETOF
PUBLISHED FOR OPPOSITION
Jan 14, 2025 PUBO
NOTICE OF PUBLICATION
Jan 8, 2025 NPUB
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 17, 2024 CNSA
NEW REPRESENTATIVE AT IB RECEIVED
Jul 6, 2024 NREP
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
Jun 30, 2024 OPNX
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Jun 20, 2024 RFWR
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Jun 7, 2024 OPNS
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
Jun 7, 2024 OPNR
NEW REPRESENTATIVE AT IB RECEIVED
May 20, 2024 NREP
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Aug 24, 2023 RFCR
NON-FINAL ACTION WRITTEN
Aug 23, 2023 CNRT
NON-FINAL ACTION (IB REFUSAL) WITHDRAWN FOR REVIEW
Aug 22, 2023 RFWR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Jul 29, 2023 RFCR
NON-FINAL ACTION WRITTEN
Jul 28, 2023 CNRT
ASSIGNED TO EXAMINER
Jul 25, 2023 DOCK
NEW REPRESENTATIVE AT IB RECEIVED
Mar 11, 2023 NREP
APPLICATION FILING RECEIPT MAILED
Dec 31, 2022 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Dec 27, 2022 NWOS
SN ASSIGNED FOR SECT 66A APPL FROM IB
Dec 23, 2022 REPR